NOTE: Please be sure the statement in this window matches statement you are addressing within the survey.
3. The criteria used for selecting patients eligible for curative treatment after tumor downstaging should be the same as before tumor downstaging.
Do you agree with this statement?
4. 18F-FDG PET/CT should be obtained prior to SIRT when available to determine baseline function.
Do you agree with this statement?
References: SIRT with resin microspheres in non-Asian regions
Kucuk et al. Prognostic importance of 18F-FDG uptake pattern of hepatocellular cancer patients who received SIRT. Clin Nucl Med. 2013 Jul;38(7):e283-9. doi: 10.1097/RLU.0b013e3182867f17
- Retrospective single-center cohort study conducted in Turkey using resin microspheres
- Analysis of 19 patients who underwent 18F-FDG PET/CT before SIRT treatment
- Etiology not specified
- Patterns of FDG uptake were significantly correlated with progression-free survival (PFS). Median PFS for patients with hypoactive liver tumors was 5.25 ± 1.52 months, 12.3 ± 2.6 months for patients with nonhomogeneous FDG uptake, and 19.8 ± 5.0 months for patients with focal intense uptake (P=0.017)
- HCC patients with higher SUVmax lesions showed better PFS following SIRT treatment than patients with lower SUVmax lesions
Filippi et al. Decrease in total lesion glycolysis and survival after yttrium-90-radioembolization in poorly differentiated hepatocellular carcinoma with portal vein tumour thrombosis. Nucl Med Commun. 2018 Sep;39(9):845-852. doi: 10.1097/MNM.0000000000000879
- Retrospective single-center cohort study conducted in Italy using resin microspheres
- Study aim was to evaluate the change in total lesion glycolysis (TLG) as a prognostic indicator for survival outcomes in HCC patients with PVTT after SIRT treatment
- Retrospective analysis of 21 patients (33.3% HBV, 71.4% HCV, 9.5% HBV+HCV) with poorly differentiated HCC and PVTT who underwent SIRT. 18F-FDG PET-CT scans were taken at baseline and 1 month after SIRT treatment to assess decrease in total lesion glycolysis (ΔTLG) after SIRT.
- Mean overall survival was significantly longer for patients with ΔTLG > 50% (n=9) compared to patients with ΔTLG <50% (n= 12): 16.8 (95% CI 14.2-19.5) months and 7.5 (95% CI 6.5-8.6) months, respectively; p<0.001 [Table 3]
- ΔTLG as assessed by 18F-FDG PET-CT scans may be a useful indicator for treatment response and outcomes in HCC patients with PVTT who undergo SIRT
Blanc-Durand et al. Signature of survival: a 18F-FDG PET based whole-liver radiomic analysis predicts survival after 90Y-TARE for hepatocellular carcinoma. Oncotarget. 2017;9(4):4549-4558. doi: 10.18632/oncotarget.23423
- Retrospective single-center case series conducted in Switzerland using resin and glass microspheres
- Patient characteristics included unilobar (n=24) diffuse (n=18); PVI (n=21); serum AFP 17 kUI/L; BCLC A (n=3), B (N=18), C (n=26), Ascites (n=7); Child Pugh A (n=36), B (n=8); hepatitis B, C (n=17, 36.2%)
- Administered activity 1.6 GBq
- Average tumor volume was 170 cm3 and absorbed dose was 170 Gy
- 30 patients recurred at median 6.9 months; 33 died of progression
- Two difference methods were used to calculate risk related to PFS and OS and microsphere type did not affect survival using either calculation method
Pretreatment 18F-FDG PET independently predicts poor PFS and OS in patients undergoing SIRT for unresectable HCC